Dr. Kim graduated from Seoul National University College of Medicine and trained at Seoul National University Hospital Cardiovascular Surgical Residency Program and took the Advanced General Thoracic Surgical Fellowship Program at the Mayo Clinic, USA. After military service, he joined the Department of Thoracic Surgery at Seoul National University Hospital as a faculty member.
Dr. Kim is an active member of the IASLC, the American Association for Thoracic Surgery (AATS), the Society of Thoracic Surgeons (STS), and other international and domestic academic societies.
Clinically, his main interest is lung cancer surgery. Dr. Kim is one of the leading members of minimally invasive surgery and served as a board of directors for the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS).
Academically, he has been conducting lung cancer genomic research. His group discovered KIF5B-RET fusion mutation in the lung adenocarcinoma for the first time in the world. After that, using whole-genome sequencing, his group found the genomic mechanism of fusion gene formation and published it in Cell. Dr. Kim’s team has conducted various research solving the unmet needs of lung cancer genomics and leads the development of lung cancer panel tests in his institution. They established a lung alveolar organoid model to test SARS-CoV-2 infection, published in Cell Stem Cell.
As the Chairman of KALC (Korean Association for Lung Cancer), Dr. Kim believes that international collaboration is critical to achieving the goal of conquering lung cancer, and he is encouraging the active participation of KALC members in the IASLC.